Keywords: gw, drops, 546c88, septic, shock, glaxo, wellcome

GW Drops 546C88 for Septic Shock

Article | 30 April 1998

Print This

Glaxo Wellcome says that it has decided to terminate a Phase III studyof its nitric oxide synthase inhibitor 546C88 in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in